Development of a core outcome set for basal cell carcinoma

Daniel I. Schlessinger; Kelly A. Reynolds; McKenzie A. Dirr; Sarah A. Ibrahim; Arianna F. Yanes; Jake M. Lazaroff; Victoria Godinez-Puig; Brian R. Chen; Anastasia O. Kurta; Jill K. Cotseones; Sarah G. Chiren; Karina C. Furlan; Sanjana Iyengar; Ramona Behshad; Danielle M. DeHoratius; Pablo Denes; Aaron M. Drucker; Leonard M. Dzubow; Jeremy R. Etzkorn; Catherine A. Harwood; John Y.S. Kim; Naomi Lawrence; Erica H. Lee; Gary S. Lissner; Ashfaq A. Marghoob; Rubeta N. Matin; Adam R. Mattox; Bharat B. Mittal; J. Regan Thomas; Xiaolong Alan Zhou; David Zloty; Jochen Schmitt; Jamie J. Kirkham; April W. Armstrong; Nicole Basset-Seguin; Elizabeth M. Billingsley; Jeremy S. Bordeaux; Jerry Brewer; Marc Brown; Mariah Brown; Scott A.B. Collins; Maria Concetta Fargnoli; Sergio Jobim De Azevedo; Reinhard Dummer; Alexander Eggermont; Glenn D. Goldman; Merete Haedersdal; Elizabeth K. Hale; Allison Hanlon; Kelly L. Harms; Conway C. Huang; Eva A. Hurst; Gino K. In; Nicole Kelleners-Smeets; Meenal Kheterpal; Barry Leshin; Michel Mcdonald; Stanley J. Miller; Alexander Miller; Eliot N. Mostow; Myrto Trakatelli; Kishwer S. Nehal; Desiree Ratner; Howard Rogers; Kavita Y. Sarin; Seaver L. Soon; Thomas Stasko; Paul A. Storrs; Luca Tagliaferri; Allison T. Vidimos; Sandra L. Wong; Siegrid S. Yu; Iris Zalaudek; Nathalie C. Zeitouni; John A. Zitelli; Emily Poon; Joseph F. Sobanko; Todd V. Cartee; Ian A. Maher; Murad Alam

doi:10.1016/j.jaad.2022.04.059

Development of a core outcome set for basal cell carcinoma

Daniel I. Schlessinger, Kelly A. Reynolds, McKenzie A. Dirr, Sarah A. Ibrahim, Arianna F. Yanes, Jake M. Lazaroff, Victoria Godinez-Puig, Brian R. Chen, Anastasia O. Kurta, Jill K. Cotseones, Sarah G. Chiren, Karina C. Furlan, Sanjana Iyengar, Ramona Behshad, Danielle M. DeHoratius, Pablo Denes, Aaron M. Drucker, Leonard M. Dzubow, Jeremy R. Etzkorn, Catherine A. HarwoodJohn Y.S. Kim, Naomi Lawrence, Erica H. Lee, Gary S. Lissner, Ashfaq A. Marghoob, Rubeta N. Matin, Adam R. Mattox, Bharat B. Mittal, J. Regan Thomas, Xiaolong Alan Zhou, David Zloty, Jochen Schmitt, Jamie J. Kirkham, April W. Armstrong, Nicole Basset-Seguin, Elizabeth M. Billingsley, Jeremy S. Bordeaux, Jerry Brewer, Marc Brown, Mariah Brown, Scott A.B. Collins, Maria Concetta Fargnoli, Sergio Jobim De Azevedo, Reinhard Dummer, Alexander Eggermont, Glenn D. Goldman, Merete Haedersdal, Elizabeth K. Hale, Allison Hanlon, Kelly L. Harms, Conway C. Huang, Eva A. Hurst, Gino K. In, Nicole Kelleners-Smeets, Meenal Kheterpal, Barry Leshin, Michel Mcdonald, Stanley J. Miller, Alexander Miller, Eliot N. Mostow, Myrto Trakatelli, Kishwer S. Nehal, Desiree Ratner, Howard Rogers, Kavita Y. Sarin, Seaver L. Soon, Thomas Stasko, Paul A. Storrs, Luca Tagliaferri, Allison T. Vidimos, Sandra L. Wong, Siegrid S. Yu, Iris Zalaudek, Nathalie C. Zeitouni, John A. Zitelli, Emily Poon, Joseph F. Sobanko, Todd V. Cartee, Ian A. Maher, Murad Alam

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

5 Citaten (Scopus)

Samenvatting

Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions. Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials. Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group. Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome. Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies. Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

Originele taal-2	Engels
Pagina's (van-tot)	573-581
Aantal pagina's	9
Tijdschrift	Journal of the American Academy of Dermatology
Volume	87
Nummer van het tijdschrift	3
DOI's	https://doi.org/10.1016/j.jaad.2022.04.059
Status	Gepubliceerd - sep. 2022
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.jaad.2022.04.059

Citeer dit

Schlessinger, D. I., Reynolds, K. A., Dirr, M. A., Ibrahim, S. A., Yanes, A. F., Lazaroff, J. M., Godinez-Puig, V., Chen, B. R., Kurta, A. O., Cotseones, J. K., Chiren, S. G., Furlan, K. C., Iyengar, S., Behshad, R., DeHoratius, D. M., Denes, P., Drucker, A. M., Dzubow, L. M., Etzkorn, J. R., ... Alam, M. (2022). Development of a core outcome set for basal cell carcinoma. Journal of the American Academy of Dermatology, 87(3), 573-581. https://doi.org/10.1016/j.jaad.2022.04.059

@article{91266d0b555644ae93ffd0cd29191194,

title = "Development of a core outcome set for basal cell carcinoma",

abstract = "Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions. Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials. Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group. Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome. Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies. Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.",

keywords = "Carcinoma, Basal Cell/therapy, Delphi Technique, Humans, Quality of Life, Research Design, Skin Neoplasms/therapy, Treatment Outcome",

author = "Schlessinger, {Daniel I.} and Reynolds, {Kelly A.} and Dirr, {McKenzie A.} and Ibrahim, {Sarah A.} and Yanes, {Arianna F.} and Lazaroff, {Jake M.} and Victoria Godinez-Puig and Chen, {Brian R.} and Kurta, {Anastasia O.} and Cotseones, {Jill K.} and Chiren, {Sarah G.} and Furlan, {Karina C.} and Sanjana Iyengar and Ramona Behshad and DeHoratius, {Danielle M.} and Pablo Denes and Drucker, {Aaron M.} and Dzubow, {Leonard M.} and Etzkorn, {Jeremy R.} and Harwood, {Catherine A.} and Kim, {John Y.S.} and Naomi Lawrence and Lee, {Erica H.} and Lissner, {Gary S.} and Marghoob, {Ashfaq A.} and Matin, {Rubeta N.} and Mattox, {Adam R.} and Mittal, {Bharat B.} and Thomas, {J. Regan} and Zhou, {Xiaolong Alan} and David Zloty and Jochen Schmitt and Kirkham, {Jamie J.} and Armstrong, {April W.} and Nicole Basset-Seguin and Billingsley, {Elizabeth M.} and Bordeaux, {Jeremy S.} and Jerry Brewer and Marc Brown and Mariah Brown and Collins, {Scott A.B.} and Fargnoli, {Maria Concetta} and {De Azevedo}, {Sergio Jobim} and Reinhard Dummer and Alexander Eggermont and Goldman, {Glenn D.} and Merete Haedersdal and Hale, {Elizabeth K.} and Allison Hanlon and Harms, {Kelly L.} and Huang, {Conway C.} and Hurst, {Eva A.} and In, {Gino K.} and Nicole Kelleners-Smeets and Meenal Kheterpal and Barry Leshin and Michel Mcdonald and Miller, {Stanley J.} and Alexander Miller and Mostow, {Eliot N.} and Myrto Trakatelli and Nehal, {Kishwer S.} and Desiree Ratner and Howard Rogers and Sarin, {Kavita Y.} and Soon, {Seaver L.} and Thomas Stasko and Storrs, {Paul A.} and Luca Tagliaferri and Vidimos, {Allison T.} and Wong, {Sandra L.} and Yu, {Siegrid S.} and Iris Zalaudek and Zeitouni, {Nathalie C.} and Zitelli, {John A.} and Emily Poon and Sobanko, {Joseph F.} and Cartee, {Todd V.} and Maher, {Ian A.} and Murad Alam",

year = "2022",

month = sep,

doi = "10.1016/j.jaad.2022.04.059",

language = "English",

volume = "87",

pages = "573--581",

journal = "Journal of the American Academy of Dermatology",

issn = "0190-9622",

publisher = "Mosby Inc.",

number = "3",

}

Schlessinger, DI, Reynolds, KA, Dirr, MA, Ibrahim, SA, Yanes, AF, Lazaroff, JM, Godinez-Puig, V, Chen, BR, Kurta, AO, Cotseones, JK, Chiren, SG, Furlan, KC, Iyengar, S, Behshad, R, DeHoratius, DM, Denes, P, Drucker, AM, Dzubow, LM, Etzkorn, JR, Harwood, CA, Kim, JYS, Lawrence, N, Lee, EH, Lissner, GS, Marghoob, AA, Matin, RN, Mattox, AR, Mittal, BB, Thomas, JR, Zhou, XA, Zloty, D, Schmitt, J, Kirkham, JJ, Armstrong, AW, Basset-Seguin, N, Billingsley, EM, Bordeaux, JS, Brewer, J, Brown, M, Brown, M, Collins, SAB, Fargnoli, MC, De Azevedo, SJ, Dummer, R, Eggermont, A, Goldman, GD, Haedersdal, M, Hale, EK, Hanlon, A, Harms, KL, Huang, CC, Hurst, EA, In, GK, Kelleners-Smeets, N, Kheterpal, M, Leshin, B, Mcdonald, M, Miller, SJ, Miller, A, Mostow, EN, Trakatelli, M, Nehal, KS, Ratner, D, Rogers, H, Sarin, KY, Soon, SL, Stasko, T, Storrs, PA, Tagliaferri, L, Vidimos, AT, Wong, SL, Yu, SS, Zalaudek, I, Zeitouni, NC, Zitelli, JA, Poon, E, Sobanko, JF, Cartee, TV, Maher, IA & Alam, M 2022, 'Development of a core outcome set for basal cell carcinoma', Journal of the American Academy of Dermatology, vol. 87, nr. 3, blz. 573-581. https://doi.org/10.1016/j.jaad.2022.04.059

TY - JOUR

T1 - Development of a core outcome set for basal cell carcinoma

AU - Schlessinger, Daniel I.

AU - Reynolds, Kelly A.

AU - Dirr, McKenzie A.

AU - Ibrahim, Sarah A.

AU - Yanes, Arianna F.

AU - Lazaroff, Jake M.

AU - Godinez-Puig, Victoria

AU - Chen, Brian R.

AU - Kurta, Anastasia O.

AU - Cotseones, Jill K.

AU - Chiren, Sarah G.

AU - Furlan, Karina C.

AU - Iyengar, Sanjana

AU - Behshad, Ramona

AU - DeHoratius, Danielle M.

AU - Denes, Pablo

AU - Drucker, Aaron M.

AU - Dzubow, Leonard M.

AU - Etzkorn, Jeremy R.

AU - Harwood, Catherine A.

AU - Kim, John Y.S.

AU - Lawrence, Naomi

AU - Lee, Erica H.

AU - Lissner, Gary S.

AU - Marghoob, Ashfaq A.

AU - Matin, Rubeta N.

AU - Mattox, Adam R.

AU - Mittal, Bharat B.

AU - Thomas, J. Regan

AU - Zhou, Xiaolong Alan

AU - Zloty, David

AU - Schmitt, Jochen

AU - Kirkham, Jamie J.

AU - Armstrong, April W.

AU - Basset-Seguin, Nicole

AU - Billingsley, Elizabeth M.

AU - Bordeaux, Jeremy S.

AU - Brewer, Jerry

AU - Brown, Marc

AU - Brown, Mariah

AU - Collins, Scott A.B.

AU - Fargnoli, Maria Concetta

AU - De Azevedo, Sergio Jobim

AU - Dummer, Reinhard

AU - Eggermont, Alexander

AU - Goldman, Glenn D.

AU - Haedersdal, Merete

AU - Hale, Elizabeth K.

AU - Hanlon, Allison

AU - Harms, Kelly L.

AU - Huang, Conway C.

AU - Hurst, Eva A.

AU - In, Gino K.

AU - Kelleners-Smeets, Nicole

AU - Kheterpal, Meenal

AU - Leshin, Barry

AU - Mcdonald, Michel

AU - Miller, Stanley J.

AU - Miller, Alexander

AU - Mostow, Eliot N.

AU - Trakatelli, Myrto

AU - Nehal, Kishwer S.

AU - Ratner, Desiree

AU - Rogers, Howard

AU - Sarin, Kavita Y.

AU - Soon, Seaver L.

AU - Stasko, Thomas

AU - Storrs, Paul A.

AU - Tagliaferri, Luca

AU - Vidimos, Allison T.

AU - Wong, Sandra L.

AU - Yu, Siegrid S.

AU - Zalaudek, Iris

AU - Zeitouni, Nathalie C.

AU - Zitelli, John A.

AU - Poon, Emily

AU - Sobanko, Joseph F.

AU - Cartee, Todd V.

AU - Maher, Ian A.

AU - Alam, Murad

PY - 2022/9

Y1 - 2022/9

N2 - Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions. Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials. Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group. Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome. Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies. Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

AB - Background: There is variation in the outcomes reported in clinical studies of basal cell carcinoma. This can prevent effective meta-analyses from answering important clinical questions. Objective: To identify a recommended minimum set of core outcomes for basal cell carcinoma clinical trials. Methods: Patient and professional Delphi process to cull a long list, culminating in a consensus meeting. To be provisionally accepted, outcomes needed to be deemed important (score, 7-9, with 9 being the maximum) by 70% of each stakeholder group. Results: Two hundred thirty-five candidate outcomes identified via a systematic literature review and survey of key stakeholders were reduced to 74 that were rated by 100 health care professionals and patients in 2 Delphi rounds. Twenty-seven outcomes were provisionally accepted. The final core set of 5 agreed-upon outcomes after the consensus meeting included complete response; persistent or serious adverse events; recurrence-free survival; quality of life; and patient satisfaction, including cosmetic outcome. Limitations: English-speaking patients and professionals rated outcomes extracted from English language studies. Conclusion: A core outcome set for basal cell carcinoma has been developed. The use of relevant measures may improve the utility of clinical research and the quality of therapeutic guidance available to clinicians.

KW - Carcinoma, Basal Cell/therapy

KW - Delphi Technique

KW - Humans

KW - Quality of Life

KW - Research Design

KW - Skin Neoplasms/therapy

KW - Treatment Outcome

UR - http://www.scopus.com/inward/record.url?scp=85132831917&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2022.04.059

DO - 10.1016/j.jaad.2022.04.059

M3 - Article

C2 - 35551965

AN - SCOPUS:85132831917

SN - 0190-9622

VL - 87

SP - 573

EP - 581

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

IS - 3

ER -

Development of a core outcome set for basal cell carcinoma

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit